Accessibility Menu

Innate Pharma(FRA) IDD

Market Cap€210.22MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPON/A
5 YearN/A
1 YearN/A
1 MonthN/A
€1.87
-0.64%
-0.01Today

Innate Pharma Financials at a Glance

Market Cap

€210.22MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

N/A

Net Income (TTM)

N/A

EPS (TTM)

-€0.54

P/E Ratio

-3.47

Dividend

€0.00

Beta (Volatility)

-0.08 (Low)

Price

€1.87

Volume

0

Open

€1.87

Previous Close

€1.87

Daily Range

€1.87 - €1.87

52-Week Range

€1.04 - €2.16

Estimated Earnings Date

N/A

IDD News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Innate Pharma

Innate Pharma SA is a biopharmaceutical company, which engages in improving oncology treatment and clinical outcomes for patients through therapeutic antibodies that harness the immune system to fight cancer. Its product pipeline include Lacutamab, Monalizumab, Avdoralimab, and IPH62. The company was founded by Hervé Eloi Dominique Brailly, Eric Vivier, Marc Bonneville, Alessandro Moretta, Jean-Jacques Fournié, and François Romagné on September 23, 1999 and is headquartered in Marseille, France.

Industry

Biotechnology

Sector

Health Care

Employees

163

CEO

Jonathan Dickinson, MBA

Website

www.innate-pharma.com

IDD Financials

Key Financial Metrics (TTM)

Gross Margin

N/A

Operating Margin

N/A

Net Income Margin

N/A

Return on Equity

-271.38%

Return on Capital

N/A

Return on Assets

N/A

Earnings Yield

-28.82%

Dividend Yield

0.00%

Payout Ratio

N/A

Stock Overview

Market Cap

€210.22MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

111.70M

Volume

0

Avg. Volume

133.818

Financials (TTM)

Gross Profit

N/A

Operating Income

N/A

EBITDA

N/A

Operating Cash Flow

N/A

Capital Expenditure

N/A

Free Cash Flow

N/A

Cash & ST Invst.

N/A

Total Debt

N/A

Innate Pharma Performance Analysis

Innate Pharma annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31EUR 49,580,000309.3%
20232023-12-31EUR 51,901,0004.7%
20242024-12-31EUR 12,622,000-75.7%
20252025-12-31EUR 2,787,000-77.9%
Innate Pharma annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31EUR -0.739.9%
20232023-12-31EUR -0.09-87.1%
20242024-12-31EUR -0.61548.7%
20252025-12-31EUR -0.55-10.1%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
CurrentYOY CHG

Revenue

N/A

N/A

Gross Profit

N/A

N/A

Gross Margin

N/A

N/A

Market Cap

€210.22MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

N/A

N/A

Employees

N/A

N/A

Net Income

N/A

N/A

EBITDA

N/A

N/A

Quarterly Fundamentals

Name
CurrentYOY CHG

Total Cash

N/A

N/A

Total Debt

N/A

N/A

Accounts Receivable

N/A

N/A

Inventory

N/A

N/A

Long Term Debt

N/A

N/A

Short Term Debt

N/A

N/A

Return on Assets

N/A

N/A

Return on Invested Capital

N/A

N/A

Free Cash Flow

N/A

N/A

Operating Cash Flow

N/A

N/A

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
^GSPCS&P 500
$7,684.24-0.00%
^DJIDJI
$53,254.61-0.01%
^IXICNASDAQ
$26,319.55-0.00%
BTCBitcoin
$78,890.00-0.00%

Trending Stocks

Symbol / CompanyPricePrice Chg
PCGPG&E
$13.27-0.20%
NVDANvidia
$220.78+0.01%
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x ETF
$9.97+0.11%
CNHCNH Industrial
$11.83+0.01%

Questions About IDD

What is the current price of Innate Pharma?

Innate Pharma is trading at €1.87 per share.

What is the 52-week range for Innate Pharma?

Over the past 52 weeks, Innate Pharma has traded between €1.04 and €2.16.

How much debt does Innate Pharma have?

As of the most recent reporting period, Innate Pharma reported total debt of €22.57M.

How much cash does Innate Pharma have on hand?

Innate Pharma reported €28.09M in cash and cash equivalents in its most recent financial results.

What is Innate Pharma’s dividend yield?

Innate Pharma does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services